324 related articles for article (PubMed ID: 18203952)
1. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.
Yamamoto R; Nishikori M; Kitawaki T; Sakai T; Hishizawa M; Tashima M; Kondo T; Ohmori K; Kurata M; Hayashi T; Uchiyama T
Blood; 2008 Mar; 111(6):3220-4. PubMed ID: 18203952
[TBL] [Abstract][Full Text] [Related]
2. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
3. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
4. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.
Jalali S; Price-Troska T; Bothun C; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Dong H; Ansell SM
Blood Cancer J; 2019 Feb; 9(3):22. PubMed ID: 30783096
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Liu WR; Shipp MA
Blood; 2017 Nov; 130(21):2265-2270. PubMed ID: 29167175
[TBL] [Abstract][Full Text] [Related]
8. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
Muenst S; Hoeller S; Dirnhofer S; Tzankov A
Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
13. Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL.
Ohshima K; Karube K; Hamasaki M; Suefuji H; Tutiya T; Yamaguchi T; Suzumiya J; Kikuchi M
Int J Cancer; 2003 Sep; 106(5):706-12. PubMed ID: 12866030
[TBL] [Abstract][Full Text] [Related]
14. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.
Jurado JO; Alvarez IB; Pasquinelli V; Martínez GJ; Quiroga MF; Abbate E; Musella RM; Chuluyan HE; García VE
J Immunol; 2008 Jul; 181(1):116-25. PubMed ID: 18566376
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway.
Henry M; Buck S; Al-Qanber B; Gadgeel M; Savaşan S
Leuk Lymphoma; 2022 Jun; 63(6):1331-1338. PubMed ID: 35001800
[TBL] [Abstract][Full Text] [Related]
16. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
17. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Yamamoto R; Nishikori M; Tashima M; Sakai T; Ichinohe T; Takaori-Kondo A; Ohmori K; Uchiyama T
Cancer Sci; 2009 Nov; 100(11):2093-100. PubMed ID: 19703193
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
19. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
[TBL] [Abstract][Full Text] [Related]
20. RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma.
Chemnitz JM; Eggle D; Driesen J; Classen S; Riley JL; Debey-Pascher S; Beyer M; Popov A; Zander T; Schultze JL
Blood; 2007 Nov; 110(9):3226-33. PubMed ID: 17644739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
